Posted inCardiology Diabetes & Endocrinology news
Empagliflozin Demonstrates Uniform Cardiovascular Benefits Across Diverse Patient Subgroups in Type 2 Diabetes: Insights from the EMPRISE Real-World Study
Empagliflozin consistently reduces major cardiovascular events, heart failure hospitalizations, and mortality across diverse sociodemographic and cardiovascular risk groups in older adults with type 2 diabetes, with especially pronounced absolute benefits in those with existing cardiovascular disease.